WW International (WW), more commonly known as Weight Watchers, is fully embracing GLP-1 weight-loss drugs, such as Ozempic and Wegovy, following its restructuring. The company recently introduced a platform that integrates GLP-1 medications with its personalized nutrition, behavioral support, coaching, and community offerings.
In addition, the digital experience within the new platform includes Weight Health Score, a weight-scoring system, and a new artificial intelligence (AI)-powered body scanner that tracks changes in fat and muscle. WW’s stock gained 12.1% intraday on Dec. 16 on this news.
